CAGRILINTIDE SAFETY
Cagrilintide Side Effects: What Trials Report
Mostly gastrointestinal, from investigational studies
⚠ Cagrilintide is investigational; its complete safety profile is still being established through ongoing clinical trials.
Cagrilintide side effects reported so far come from clinical trials of an investigational drug, so the full safety profile is still being established. For the trial evidence, see the cagrilintide clinical trials page.
Most Commonly Reported
Like other appetite-pathway agents, the most commonly reported effects in cagrilintide trials have been gastrointestinal — such as nausea — which often ease over time. Injection-site reactions can also occur.
Source: Novo Nordisk REDEFINE clinical program reporting.
Investigational Caveat
Because cagrilintide is not yet approved, its long-term safety and complete side-effect profile are still emerging. Research-labeled cagrilintide is not the manufacturer's trial product and has not been FDA-evaluated.
Frequently Asked Questions
What are common cagrilintide side effects in trials?
Mostly gastrointestinal, such as nausea.
Is cagrilintide's safety fully established?
No. It is investigational, so the full profile is still emerging.
The Bottom Line
Cagrilintide side effects reported to date are mainly gastrointestinal, within an investigational profile that is still developing — so cagrilintide side effects should be read as preliminary.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- Novo Nordisk REDEFINE clinical program reporting
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →